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The International Association for the Study of Pain
defines central pain as “pain initiated or caused by
primary lesion or dysfunction of the central nervous
system” [1]. If it results from a stroke, it is referred to
as central poststroke pain (CPSP) [1]. CPSP prevalence
reports vary from 8% to 46% [2-4]. This wide variation is
possibly related to the heterogeneity of stroke lesions
between the populations surveyed, differences in study
design, and different timing of evaluations after stroke
[5]. CPSP continues to be an under-recognized compli-
cation despite its potential to impair activities of daily
living (ADL), deteriorate quality of life, and undermine
rehabilitation programs [6,7]. Treatment of CPSP re-
mains a challenge because of the limited efficacy of
options available and their adverse effects. Current
therapeutic options include antidepressants, anticon-
vulsants, opioids, and neurostimulation therapy.
Botulinum neurotoxin (BoNT) has been approved
worldwide for use in persons with movement disorders.
Early in the use for cervical dystonia, several authors
noted an analgesic effect that preceded and exceeded
what would have been expected solely as a conse-
quence of muscle relaxation [8]. Since then, several
studies have been conducted to investigate its analgesic
action, and in October 2010, onabotulinum toxin A was
approved by the United States Food and Drug Adminis-
tration for chronic migraine. Several studies and reports
have suggested the efficacy of BoNT in treating neuro-
pathic pain syndromes, including postherpetic neuralgia
[2], post-traumatic/postoperative neuropathies [1], and
trigeminal neuralgia [3]. We conducted a search of the
scientific literature and found 2 documented cases
concerning central pain and BoNT use, but both were
related to treatment of central pain in spinal cord
injury. No case reports were found regarding CPSP and
BoNT use. In this article we report the first cases of
patients with CPSP who were treated with BoNT for
their spasticity and concomitantly showed a decrease in
the intensity of their CPSP.1934-1482/$ - see front matter ª 2016 by the American Academy of Physi
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A 48-year-old right-handed white woman with a
medical history of depression experienced an ischemic
stroke affecting the right cerebral hemisphere (the
vascular territory of the right anterior and middle ce-
rebral arteries). She required a right frontal decom-
pressive craniectomy with subsequent cranioplasty.
After clinical stabilization, she was admitted to an
inpatient comprehensive rehabilitation program that
focused on motor re-education, ADL training, and
cognitive stimulation; this program lasted 3 months. She
was then discharged and participated in an outpatient
rehabilitation program for about a year and a half, after
which she was referred to our outpatient spasticity
clinic.
On clinical examination the patient presented with
left spastic hemiparesis, without selected active
movements in her upper or lower limbs. With regard to
spasticity, the mean score on the Ashworth Scale was
2.44 in the upper limb and 1.6 in the lower limb. She
also presented with left hemibody severe mechanical
allodynia (rated 8/10 on the numeric pain scale). She
described this pain as being generated by the brushing
of garments on her skin; it started 3 months after the
stroke occurred and did not progress in intensity (it was
graded as “severe” from the beginning). No quality of
life scales or questionnaires were used, but she
mentioned that these symptoms severely impaired her
quality of life. She took the following oral medications:
valproate, 500 mg twice a day; agomelatine, 25 mg
every day; pregabalin, 50 mg twice a day; atorvastatin,
20 mg every day; acetylsalicylic acid, 150 mg every day;
omeprazole, 20 mg every day; tizanidine, 6 mg every
day; and baclofen, 10 mg three times a day. The patient
was considered for BoNT treatment to reduce the
spastic patterns of her adducted/internally rotated
shoulder, flexed wrist, and clenched fist and thus, it was
hoped, to improve active functionality in ADL. One
week later we injected abobotulinum toxin A, recon-
stituted in 2.5 mL of sodium chloride 0.9% solutioncal Medicine and Rehabilitation
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myographic (EMG) guidance, into the following muscles:
pectoralis major (50 U), subscapularis (50 U), pronator
teres (25 U), flexor carpi radialis (25 U), and flexor carpi
ulnaris (25 U). At 1-month follow-up the patient dis-
played an improvement in spastic patterns (the mean
score in the Ashworth Scale was 1.77 in the upper limb),
as well as a reduction of her mechanical allodynia in the
left upper limb (according to the numeric pain scale the
intensity changed from 8 to 6) but not in the left lower
limb (which remained 8 on the numeric pain scale). (We
used the numeric pain scale, which has a standardized
application procedure. We presented it to the patients
and asked them to grade the severity of their me-
chanical allodynia, in the past week, considering that
0 ¼ no pain and 10 ¼ the worst imaginable pain.) The
patient noticed this effect around 15 days after
receiving the injection. She reported this effect as an
improvement in her skin tolerance to garments, and she
denied experiencing any adverse events. At the 3-
month follow-up, she showed recurrence of her upper
limb spasticity (a mean Ashworth score in the upper
limb of 2.3), but experienced a persistent reduction of
the left upper limb allodynia (which remained graded as
6/10). At this time, she received another injection with
BoNT for her spasticity: pectoralis major (200 U), sub-
scapularis (100 U), latissimus dorsi (200 U), flexor carpi
radialis (100 U), flexor carpi ulnaris (100 U), flexor
digitorum sublimis (100 U), flexor digitorum profundus
(100 U), adductor pollicis (30 U), and flexor pollicis
longus (50 U). Two months later we performed a tele-
phone interview, and she reported an improvement in
spastic patterns (we could not objectively evaluate
muscle tone via the telephone). She reported that she
had maintained the same magnitude of reduction of
mechanical allodynia (rated 6/10). She denied experi-
encing any adverse events.
Case 2
A 57-year-old right-handed white man with a medical
history of diabetes mellitus type 2 and primary arterial
hypertension experienced a hemorrhagic stroke of the
left cerebral hemisphere (frontal and parietal lobes) in
2005. Ever since, he had been integrated in an outpa-
tient rehabilitation program and was referred to our
outpatient-based spasticity clinic in 2013. On clinical
examination we found global aphasia and right spastic
hemiparesis with no active movements in the upper
limb and poorly selective active movements in the
lower limb (“en bloc” movements). With regard to
spasticity, the mean score in the Ashworth Scale was
2.3 in the upper limb and 3 in the lower limb. He also
presented with right hemibody mechanical allodynia of
moderate intensity (rated 6/10 on the numeric pain
scale). No previous diagnosis had been made, nor did
the caretakers seem to be aware of this condition,probably because of the patient’s poor comprehension
and motor fluency. Past details about allodynia (dura-
tion, course, and impact on life) were not reliable
because of his poor comprehension and decreased
fluency. Only simple data, such as the presence and
intensity of allodynia, were reliably obtainable. He was
considered for BoNT chemodenervation with the ob-
jectives of reducing the following spastic patterns:
flexed elbow, clenched fist, pes equinus, and flexed
toes. One week later he received an injection of inco-
botulinumtoxin A (diluted in 2 mL of normal saline
solution; 50 U per milliliter of saline solution) under
EMG guidance in the following muscles: biceps brachii
(100 U); brachioradialis (50 U); flexor digitorum sublimis
(50 U); flexor digitorum profundus (50 U); gastrocne-
mius (medial head 50 U, lateral head 50 U); and flexor
digitorum longus (50 U). Upon re-evaluation after 1
month, he showed reduced spastic patterns (mean
score in the Ashworth Scale for the muscle tone in the
upper limb 1.5 and 2 in the lower limb), as well as a
decrease of the mechanical allodynia intensity from 6/
10 to 3/10 on the numeric pain scale. At the 3-month
follow-up he maintained the improvement in allodynia
intensity (rated 3/10) but presented with an increase in
muscle tone (a mean grade of 2 in the upper limb and
2.5 in the lower limb). This patient denied experiencing
any adverse events.
Discussion
Patients with CPSP may evidence allodynia that can
be evoked by tactile stimuli, cold, or muscle contraction
[9]. The most frequent form is pure mechanical allody-
nia, but multiple stimulus-evoked allodynia is also
possible [9]. The type, location, and intensity may
depend on the location and severity of the brain lesion.
In some studies, brainstem or thalamic lesions were
related to higher pain intensities. Pure tactile allodynia
is associated with ventrolateroposterior thalamic le-
sions, whereas cold allodynia tends to have more
dorsally placed thalamic lesions, and movement-evoked
allodynia has more anteriorly located lesions [9].
BoNT is a unique candidate for inhibition of pain
transmission in CPSP. The light chain of BoNT-A func-
tions as an endopeptidase that, in the presence of zinc,
deactivates the synaptosomal-associated protein of
Mr25,000 (SNAP-25) located in the cell membrane,
leading to an inability of the acetylcholine vesicle to
merge with the cell membrane [5]. However, SNAP-25
was also identified in sensory neurons, and the verifi-
cation of its cleavage by BoNT-A led to the development
of several hypothetical mechanisms of action. Recent
behavioral and immunohistochemical studies indicate
that the antinociceptive action occurs primarily in the
central nervous system [8,10,11]. BoNT-A is long-
distance retrogradely transported to the CNS in cholin-
ergic axons [9,12]. In short, it was demonstrated in
386 Analgesic Effect of BoNT in CPSPneuropathic pain models that a bilateral analgesic ef-
fect exists after unilateral toxin injection [9,12], along
with prevention of BoNT-induced antinociceptive effect
by the axonal transport-blocker colchicine [8,10,13]. At
the level of the spinal cord, in vivo experiments showed
that BoNT-A inhibits the release of pain peptides, sub-
stance P, bradykinin, calcitonin geneerelated peptide,
and glutamate from the dorsal root [14].
On the other hand, using an antibody specific for
BoNT-Aecleaved SNAP-25, a group of investigators
discovered axonal and transynaptic transport of BoNT-A
in the brain (between the 2 hippocampi) and from the
periphery to the facial motor nucleus [9]), as well as to
the spinal cord dorsal and ventral horns via the sciatic
nerve [12]. An in vivo animal experiment revealed that
BoNT-A blocks glutamate exocytosis from synapto-
somes, modifying or even preventing the development
of central pain by group I metabotropic glutamate re-
ceptors [15]. Another study showed that femtomolar
concentrations of BoNT-A inhibit membrane Naþ chan-
nels in rat central neurons, which may be implicated in
central pain transmission mechanisms [15]. Specifically
regarding allodynia, one experiment in diabetic rats
with bilateral allodynia showed that unilateral subcu-
taneous injection of BoNT-A in the allodynic region of
one affected limb improved allodynia in both limbs,
further indicating a central analgesic effect of the toxin
[11]. All these experiments suggest that retrograde
axonal transport to the CNS is responsible for the anti-
nociceptive activity of BoNT-A. It could be assumed
that, in sensory areas of the CNS, BoNT-A directly or
indirectly affects central neurotransmitters involved in
pain processing [13].
The 2 patients we described received intramuscular
injections of BoNT, and in addition to the muscle tone
decrease, they presented with a somewhat unexpected
and long-lasting relief of their CPSP. Oral medications,
including antidepressants and anticonvulsants, did not
seem to provide an acceptable analgesic effect. A lim-
itation to the explanation for our findings is that we
cannot exclude a decrease in muscle tone as the cause
of the reduction of pain. Nonetheless, this does not
seem to be the case, because the analgesic effect lasted
longer than the muscle tone reduction. Although no
decrease of the magnitude of the analgesic effect
occurred during the 3-month interval between BoNT-A
injections, it is possible that it lessens with time. We
also recognize that the utilization of the numeric pain
scale represents a limitation in itself and as the only
endpoint used. More studies are necessary to further
explore the analgesic effect of BoNT in CPSP and to
clarify its therapeutic mechanism. Functional measures
and use of other validated pain scales (e.g., the Brief
Pain Inventory) would enhance the value of any future
studies.Conclusion
Increasing evidence supports the analgesic effect of
BoNT, which potentially has a dual mechanism: pe-
ripheral and central. It has been studied and proved
effective in relieving pain, namely in persons with
chronic migraine. Our 2 stroke patients presented
with CPSP and spastic hemiplegia and were treated
with intramuscular injections of BoNT-A; they experi-
enced a modest relief of their CPSP that seemed to be
independent from the muscle tone reduction. More
clinical research is needed to see if our findings are
reproducible and to clarify the pain relief mechanism.
As in other pain syndromes, BoNT may have a future
role in the treatment of CPSP.
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